Project Grant HT94252411035
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Austin, TX 78756, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,002,591.00 to Targepeutics, Inc. to determine the intratumoral drug distribution of the immunotoxin GB13 for the treatment of adult and pediatric brain cancers. The 3-year project aims to transform health care for Service Members and the American public through innovative and impactful biomedical research on medical solutions for the battlefield. The...
This $240,897 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will support integrative transcriptomic and epigenomic profiling of subependymal giant cell astrocytoma at single-cell resolution. The award was made to Duke University's Office of Research Administration on August 1, 2025, with a period of performance through July 31, 2027. The Military Medical Research and Development program funds advanced biomedical...
The federal Project Grant award of $624,000.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award, with a performance period from September 1, 2025, to August 31, 2027, will fund a comprehensive in vivo phenotyping study of fusion-driven pediatric rhabdomyosarcomas conducted by the...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This $626,000 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports Emory University's research on developing immune-competent 3D bioprinted organoids to study and target barriers to cellular therapy for neuroblastoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions. The 2-year award period runs from July 15, 2025 to July...
The federal Project Grant award of $109,632 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Radar Therapeutics Inc. in Berkeley, CA. The award, effective August 1, 2025 through July 31, 2026, will support research on the "Selective Translation of LNP-Delivered mRNA for Precision Therapeutics in Rare Cancers including Peripheral T-Cell Lymphoma." This advanced biomedical research aims to transform healthcare for...